FATE - Fate Therapeutics GAAP EPS of -$0.72 misses by $0.04 revenue of $17.07M beats by $5.52M February, 28 2022 04:01 PM Fate Therapeutics Inc. Fate Therapeutics press release (NASDAQ:FATE): Q4 GAAP EPS of -$0.72 misses by $0.04. Revenue of $17.07M (+7.4% Y/Y) beats by $5.52M. For further details see: Fate Therapeutics GAAP EPS of -$0.72 misses by $0.04, revenue of $17.07M beats by $5.52M